Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Genentech Plans Avastin Glioblastoma sBLA In 2008

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Biotech’s Phase III program is focused on line extensions, but earlier-stage pipeline includes multiple NMEs.

You may also be interested in...



Roche Global Head Of Pharma Partnering Dan Zabrowski: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)

Zabrowski’s number one concern? Filling the gap when products go off patent.

Roche Global Head Of Pharma Partnering Dan Zabrowski: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)

Zabrowski’s number one concern? Filling the gap when products go off patent.

Avastin Misses Overall-survival Endpoint In Lung Cancer

Analysts expect minimal damage to sales as a result of AVAiL data.

Table

View full table

Related Content

Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

Global Pharma Guidance Tracker – March 2024

See All
UsernamePublicRestriction

Register

PS067410

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By